Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Gefitinib in Lenvatinib-resistant HCC
NCT04642547Completed
- Sponsor
- Renji Hospital
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gefitinib in hepatocellular carcinoma (HCC), sponsored by Renji Hospital. Primary endpoint: Progression Free Survival at 6 months. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04642547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04642547.